>유럽 알파-1 항트립신 결핍증(AATD) 증강 요법 시장, 약물별(프로라스틴, 제마이라/레스프리자, 글라시아, 아랄라스트 NP 및 기타), 유전자 유형(PiZZ 유형, PiMS 유형, PiMZ 유형 및 기타), 응용 분야(폐 질환 및 간 질환), 인구 유형(성인 및 소아), 최종 사용자( 병원 , 전문 클리닉, 재택 의료 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타) 산업 동향 및 2029년까지의 예측.
유럽 알파-1 항트립신 결핍증(AATD) 증강 요법 시장 분석 및 통찰력
알파-1 항트립신 결핍증(AATD)은 간이 알파-1 항트립신이라는 단백질을 분비하지 못할 때 발생하는 질환으로, 이 단백질은 신체의 조직이 신체의 분비 효소에 의해 공격받지 않도록 보호하는 것과 같은 다양한 기능을 위해 혈류 로 방출되어야 합니다 . 이 유전적 질환은 치료하지 않으면 폐나 간 질환으로 진행될 수 있습니다. 이 결핍증이 있는 대부분의 환자는 단백질이 적거나 단백질을 전혀 생성하지 않아 기능을 상실하게 되고, 이로 인해 간 세포 내에서 비정상적인 단백질이 생성되어 간 손상이 발생합니다.
증강 요법은 AATD 관련 폐 질환 환자에게 허가된 유일한 특정 치료법입니다. 이 요법은 건강한 기증자의 혈액에서 추출한 알파-1 항트립신 단백질을 사용하여 AAT 결핍 환자의 폐에서 단백질 양을 증가시킵니다. 이 요법은 대체 요법 이라고도 하지만 이미 발생한 폐 손상을 되돌릴 수는 없지만 폐 기능의 추가 악화를 늦출 수 있습니다. 단백질은 일반적으로 바늘을 삽입하여 정맥 주사로 투여됩니다.
유럽 알파-1 항트립신 결핍증(AATD) 증강 요법 시장은 2022년에서 2029년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년 1억 7,924만 달러에서 2029년까지 3억 1,765만 달러에 도달할 것으로 예상하고 2022년에서 2029년의 예측 기간 동안 8.3%의 CAGR로 성장할 것으로 분석했습니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
|
양적 단위 |
수익(백만 달러), 가격(달러) |
|
다루는 세그먼트 |
약물별(Prolastin, Aralast NP, Zemaira/Respreeza, Glassia 및 기타), 유전자 유형(Pimz 유형, Pims 유형, Pizz 유형 및 기타), 응용 프로그램(폐 질환 및 간 질환), 인구 유형(성인 및 소아), 최종 사용자(병원, 전문 클리닉, 가정 의료 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타) |
|
적용 국가 |
독일, 영국, 프랑스, 이탈리아, 스페인, 네덜란드, 스위스, 러시아, 터키 및 기타 유럽 |
|
시장 참여자 포함 |
Grifols, S.A. (Spain), CSL, Kamada Pharmaceuticals., Takeda Pharmaceutical Company Limited., and LFB BIOMEDICAMENTS. The Pipeline companies which are dealing in market includes Arrowhead Pharmaceuticals, Inc., Mereo BioPharma Group plc, Inhibrx, Inc., Centessa Pharmaceuticals (Z Factor)., Intellia Therapeutics, Inc., Apic Bio, Krystal Biotech, Beam Therapeutics, and LOGICBIO THERAPEUTICS, INC., among others |
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics
Drivers
- Rise in Incidence and Prevalence of AATD
With the increase prevalence and incidence of AATD worldwide, there is an increase in the demand for effective therapy products which will increase in upcoming years. Therefore, rising incidences are expected to act as a driver for the growth of the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.
- Wide Range of Risks And Comorbidities with AATD
Another significant factor influencing the growth rate of alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is the wide range of risks and comorbidities with AATD. External factors such ach smoking and alcohol consumption also affect severe outcomes directly. Progressive risk to live and lung health will aid the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.
- Improving Diagnostic Techniques for Genetic Disorders
Growing prevalence of alpha-1 antitrypsin deficiency (AATD) in various regions worldwide and various infections associated with it are expected to act as drivers for development in rare disease diagnostics. Accurate and reliable diagnosis can lead to better quality of life for patients and hence the growth of alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.
Furthermore, improved technology for production and purification methods of AAT, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.
Opportunities
- Growing R & D Activities
The Europe food and drug has approved several products currently available in the United States to treat emphysema in patients with AATD. However complete cure for alpha-1 antitrypsin deficiency (AATD) does not exist and hence gives way for new research and opportunity for development of better more effective therapies.
Also, the strategic initiatives by key players and rise in healthcare expenditure will provide structural integrity and future opportunities for the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market in the forecast period of 2022-2029.
Restraints/Challenges
However, high cost of therapies and side effects and complications of augmentation therapies will impede the growth rate of alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. Additionally, difficulty in specific identification and stringent rules and regulations will further challenge the market in the forecast period mentioned above.
This alpha-1 antitrypsin deficiency (AATD) augmentation therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on alpha-1 antitrypsin deficiency (AATD) augmentation therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Post COVID-19 Impact on Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in sepsis medication adherence during the pandemic.
Recent Development
- In October, 2020, Takeda Pharmaceutical Company Limited announced the collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc. to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD).
The Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Scope
The Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy market is segmented into techniques and test type. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Drugs
- Prolastin
- Aralast NP
- Zemaira/Respreeza
- Glassia
- Others
On the basis of drugs, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into prolastin, aralast NP, zemaira/respreeza, glassia and others.
Gene Type
- Type PIMZ
- Type PIMS
- Type PIZZ
- Others
On the basis of gene type, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into type PiMZ, type PiMS, type PiZZ and others.
Application
- Lung Disease
- Liver Disease
On the basis of application, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into lung disease and liver disease.
Population Type
- Adults
- Pediatric
On the basis of population type, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into adults and pediatric.
End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
On the basis of end user, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into hospitals, specialty clinics, home healthcare, and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Regional Analysis/Insights
The alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is analysed and market size insights and trends are provided by country, drugs, gene type, population type, application, end user and distribution channel as referenced above.
The countries covered in the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market report are Germany, U.K., France, Italy, Spain, Netherlands, Switzerland, Russia, Turkey and Rest of Europe.
Germany dominates the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the increasing healthcare expenditure in Germany, remaining at the highest level among European Union member states, is further improving the country’s market growth.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Share Analysis
알파-1 항트립신 결핍증(AATD) 증강 요법 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위에 제공된 데이터 포인트는 회사의 알파-1 항트립신 결핍증(AATD) 증강 요법 시장에 대한 초점과만 관련이 있습니다.
알파-1 항트립신 결핍증(AATD) 증강 요법 시장에서 활동하는 주요 기업으로는 Grifols, SA(스페인), CSL, Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, LFB BIOMEDICAMENTS가 있습니다. 이 시장에서 거래하는 파이프라인 기업으로는 Arrowhead Pharmaceuticals, Inc., Mereo BioPharma Group plc, Inhibrx, Inc., Centessa Pharmaceuticals(Z Factor), Intellia Therapeutics, Inc., Apic Bio, Krystal Biotech, Beam Therapeutics, LOGICBIO THERAPEUTICS, INC. 등이 있습니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DRUGS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL
4.3 PORTER'S FIVE
4.4 PIPELINE ANALYSIS
5 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: REGULATIONS
5.1 REGULATION IN U.S.:
5.2 REGULATION IN EUROPE:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN INCIDENCE AND PREVALENCE OF AATD
6.1.2 WIDE RANGE OF RISKS AND COMORBIDITIES WITH AATD
6.1.3 IMPROVING DIAGNOSTIC TECHNIQUES FOR GENETIC DISORDERS
6.1.4 IMPROVED TECHNOLOGY FOR PRODUCTION AND PURIFICATION METHODS OF AAT
6.2 RESTRAINTS
6.2.1 HIGH COST OF THERAPIES
6.2.2 SIDE EFFECTS AND COMPLICATIONS OF AUGMENTATION THERAPIES
6.3 OPPORTUNITIES
6.3.1 GROWING R & D ACTIVITIES
6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS
6.3.3 RISE IN HEALTHCARE EXPENDITURE
6.4 CHALLENGES
6.4.1 DIFFICULTY IN SPECIFIC IDENTIFICATION OF AATD
6.4.2 STRINGENT RULES AND REGULATIONS
7 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS
7.1 OVERVIEW
7.2 PROLASTIN
7.3 ZEMAIRA/RESPREEZA
7.4 GLASSIA
7.5 ARALAST NP
7.6 OTHERS
8 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE
8.1 OVERVIEW
8.2 TYPE ‘PIZZ’
8.3 TYPE ‘PIMS’
8.4 TYPE ‘PIMZ’
8.5 OTHERS
9 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 LUNG DISEASE
9.2.1 EMPHYSEMA
9.2.2 COPD
9.2.3 LUNG CANCER
9.3 LIVER DISEASE
9.3.1 CIRRHOSIS
9.3.2 HEPATITIS
9.3.3 LIVER FAILURE
10 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 PEDIATRIC
11 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
11.4 HOME HEALTHCARE
11.5 OTHERS
12 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 RETAIL PHARMACY
12.4 ONLINE PHARMACY
12.5 OTHERS
13 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 U.K.
13.1.3 FRANCE
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 NETHERLANDS
13.1.7 SWITZERLAND
13.1.8 RUSSIA
13.1.9 TURKEY
13.1.10 REST OF EUROPE
14 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 GRIFOLS, S.A.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 CSL
16.2.1 COMPANY SNAPSHOT
16.2.2 PRODUCT PORTFOLIO
16.2.3 RECENT DEVELOPMENT
16.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENT
16.4 KAMADA PHARMACEUTICALS
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 LFB BIOMEDICAMENTS
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT DEVELOPMENT
16.6 APIC BIO
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 ARROWHEAD PHARMACEUTICALS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BEAM THERAPEUTICS
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 CENTESSA PHARMACEUTICALS (Z FACTOR)
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 INHIBRX, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 INTELLIA THERAPEUTICS, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 KRYSTAL BIOTECH
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 LOGICBIO THERAPEUTICS, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 MEREO BIOPHARMA GROUP PLC
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
표 목록
TABLE 1 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, PIPELINE ANALYSIS
TABLE 2 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 3 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 5 U.S. LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 6 U.S. LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 8 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 9 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 10 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 11 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 12 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 19 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 20 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 21 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 22 GERMANY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 23 GERMANY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 24 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 25 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 27 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 28 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 29 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 30 U.K. LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 U.K. LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 32 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 33 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 36 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 37 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 38 FRANCE LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 39 FRANCE LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 40 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 41 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 42 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 43 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 44 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 45 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 ITALY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 47 ITALY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 48 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 49 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 50 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 51 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 52 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 53 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 54 SPAIN LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 SPAIN LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 57 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 60 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 61 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 62 NETHERLANDS LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 NETHERLANDS LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 64 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 65 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 66 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 68 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 69 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 SWITZERLAND LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 71 SWITZERLAND LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 72 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 73 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 75 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 76 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 77 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 78 RUSSIA LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 79 RUSSIA LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 80 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 81 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 83 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 84 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 85 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 TURKEY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 TURKEY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 89 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 REST OF EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: SEGMENTATION
FIGURE 2 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE AND AWARENESS OF AATD IS EXPECTED TO DRIVE THE EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 PROLASTIN SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET
FIGURE 14 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS, 2021
FIGURE 15 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS, CAGR (2022-2029)
FIGURE 17 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 18 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY GENE TYPE, 2021
FIGURE 19 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY GENE TYPE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY GENE TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY GENE TYPE, LIFELINE CURVE
FIGURE 22 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY APPLICATION, 2021
FIGURE 23 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 25 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY POPULATION TYPE, 2021
FIGURE 27 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 29 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 30 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY END USER, 2021
FIGURE 31 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 32 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY END USER, CAGR (2022-2029)
FIGURE 33 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 36 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: SNAPSHOT (2021)
FIGURE 39 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY COUNTRY (2021)
FIGURE 40 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS (2022-2029)
FIGURE 43 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
